GLP-1 Pills Are On The Way. Here's What To Know

The podcast explores the science and potential of new weight loss medications, specifically focusing on GLP-1 drugs and the development of oral alternatives to injections like Ozempic and Wigovi. Sydney Lupkin interviews Andrea Trena from Novo Nordisk, who explains how GLP-1 hormones work and how semaglutide was engineered to last longer in the body. The discussion covers the challenges of creating a semaglutide pill, which led to the development of SNAC, a protective buffer. Additionally, the podcast introduces Eli Lilly's new pill, Orphaglipron, and compares its efficacy to Novo Nordisk's semaglutide pill, noting the potential for pills to offer a more affordable and accessible option for weight loss management.